Diabetes and tuberculosis: a review of the role of optimal glycemic control
Tóm tắt
Developing countries shoulder most of the burden of diabetes and tuberculosis. These diseases often coexist. Suboptimal control of diabetes predisposes the patient to tuberculosis, and is one of the common causes of poor response to anti-tubercular treatment. Tuberculosis also affects diabetes by causing hyperglycemia and causing impaired glucose tolerance. Impaired glucose tolerance is one of the major risk factors for developing diabetes. The drugs used to treat tuberculosis (especially rifampicin and isoniazid) interact with oral anti-diabetic drugs and may lead to suboptimal glycemic control. Similarly some of the newer oral anti-diabetic drugs may interact with anti-tuberculosis drugs and lower their efficacy. Therefore diabetes and tuberculosis interact with each other at multiple levels – each exacerbating the other. Management of patients with concomitant tuberculosis and diabetes differs from that of either disease alone. This article reviews the association between diabetes and tuberculosis and suggests appropriate management for these conditions.
Tài liệu tham khảo
Morton R: Phthisiolgia: or a treatise of consumptions. London: Smith and Walford; 1694.
Rajalakshmi S, Veluchamy G: Yugi's pramegam and diabetes mellitus: an analogue. Bull Indian Inst Hist Med Hyderabad. 1999, 29(1):83–7.
West KM: Epidemiology of diabetes and its vascular lesions. New York: Elsevier; 1978:351.
Tattersall RB, Gale EAM: Infections. In Diabetes, clinical management. Edited by: Tattersall RB, Gale EAM. Edinburgh: Churchill Livingstone; 1990:358–364.
Wilson RM: Infection and diabetes mellitus. In Textbook of diabetes. Edited by: Pickup JC, Williams G. Oxford: Blackwell Scientific Publication; 1991:813–9.
Ruslami R, Aarnoutse RE, Alisjahbana B, Van Der Ven AJAM, Van Crevel R: Implications of the global increase of diabetes for tuberculosis control and patient care. Trop Med & Int Health 2010, 15: 1289–1299. https://doi.org/10.1111/j.1365-3156.2010.02625.x
Nijland HMJ, Ruslami R, Stalenhoef JE, Nelwan EJ, Alisjahbana B, Nelwan RHH, et al.: Exposure to rifampicin is strongly reduced in patients with tuberculosis and type 2 diabetes. Clin Infect Dis 2006, 43(7):848–854. https://doi.org/10.1086/507543
Winterbauer R, Bedon G, Ball W: Recurrent Pneumonia: Predisposing illness and clinical pattern of 158 patients. Ann Intern Med 1969, 70: 689.
Stevenson CR, Critchley JA, Forouhi NG, Roglic G, Williams BG, Dye C, et al.: Diabetes and the risk of tuberculosis: a neglected threat to public health? Chronic Illn 2007, 3: 228–45. https://doi.org/10.1177/1742395307081502
Restrepo BI: Convergence of the tuberculosis and diabetes epidemics: Renewal of old acquaintances. Clin Infect Dis 2007, 45(4):436–438. https://doi.org/10.1086/519939
Jeon C, Murray M: Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. PLoS Med 2008, 5: e152. https://doi.org/10.1371/journal.pmed.0050152
Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purva AM, Ahmad Y, Ottenhoff TH, et al.: The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007, 45: 428–35. https://doi.org/10.1086/519841
Swai AB, McLarty DG, Mugusi F: Tuberculosis in diabetic patients in Tanzania. Trop Doct. 1990, 20(4):147–50.
Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff THM, et al.: The effect of diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. Clin Infect Dis 2007, 45(4):428–435. https://doi.org/10.1086/519841
Englebach K: Passagerer diabetes mellitus bei 2 Tuberkulosekranken [Transitory diabetes mellitus in two tuberculotics.]. J Beitr Klin Tuberk Spezif Tuberkuloseforsch 1954, 110: 470–3.
Nichols GP: Diabetes among young tuberculous patients; a review of the association of the two diseases. Am Rev Tuberc 1957, 76: 1016–30.
Mugusi F, Swai A, Alberti K, Melarty G: Increased prevalence of diabetes mellitus in patients with pulmonary tuberculosis in Tanzania. Tubercle 1990, 71: 271–6. https://doi.org/10.1016/0041-3879(90)90040-F
Jeon CY, Harries AD, Baker MA, Hart JE, Kapur A, Lönnroth K, et al.: Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health 2010, 15: 1300–1314. https://doi.org/10.1111/j.1365-3156.2010.02632.x
Guptan A, Shah A: Tuberculosis and diabetes: an appraisal. Ind J Tub 2000, 47(3):2–8.
Geevarghese PJ: Pancreatic diabetes. Popular Prakashan: Bombay; 1967:26–28.
Geerlings SC, Hopelman AI: Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999, 26: 259–65. https://doi.org/10.1111/j.1574-695X.1999.tb01397.x
Tsukaguchi K, Yoneda T, Yoshikawa M: Case study of interleukin-1 beta, tumor necrosis factor alpha and interleukin-6 production by peripheral blood monocytes in patients with diabetes mellitus complicated by pulmonary tuberculosis. Kekkaku 1992, 67: 755–60.
Sidibe EH, Sankale M: Diabetes and pulmonary tuberculosis: epidemiology, pathophysiology and symptomatology. J French Stud Res Health 2007, 17(1):29–32.
Rodbard HW, Jelleinger PS, Davidson JA, et al.: Statement by an AACE/ACE Consensus Panel on type 2 diabetes mellitus An algorithm for glycemic control. Endocrine Practice 2009, 15(6):540–559.
Kalra S, Kalra B, Sharma A: Ketonuria and ketonemia in type 2 diabetes mellitus patients attending an Indian endocrine clinic. Ind J Endocr & Metab 2007, 11(3–4):7–10.
Kalra S, Kalra B, Nanda G: OPD management of ketosis in pregnancy: aspart vs. regular insulin. Diabetic Med 2006, 23(4):504.
Kalra S: Walking the tightrope in critical care: role of rapid-acting analogue insulin. In Medicine Update 2009 (Vol 19 Part I). 19th edition. Edited by: Agarwal AK. New Delh: Jay Pee Bros; 2009:388–394.
Kalra S, Kalra B, Sharma A, Chhabra B: Dosage frequency of premixed aspart insulin: clinical correlates of three-dose. Diabetes 2008, 57(1):570.
Rao PV: Persons with type 2 diabetes and co-morbid active tuberculosis should be treated with insulin. Int J Diab Dev Countries 1999, 19: 79–86.
Atkin SL, Masson EA, Bodmer CW, Walker BA, White MC: Increased insulin requirement in a patient with Type 1 diabetes on rifampicin [letter]. Diabet Med 1993, 10: 392. https://doi.org/10.1111/j.1464-5491.1993.tb00086.x
Lebovitz HE: Oral hypoglycemic agents. Ellenberg and Rifkins’s diabetes mellitus, theory and practice. 4th ed. New York: Elsevier: Rifkin H, Porte Jr D, eds; 1990:554–574.
Madsbad S: Treatment of type 2 diabetes with incretin-based therapies. Lancet 2009, 373(9662):438–439. 10.1016/S0140-6736(08)61247-7